JCR Pharmaceuticals Co.,Ltd.
FY2026 Second Quarter Results Briefing Session Material
Filed with TSE ·
6ix is reading this filing.
View original source (TDnet)JCR Pharmaceuticals Co., Ltd. on 6ix
In the deck
Story so far
Earlier from JCR Pharmaceuticals
- Italfarmaco and JCR Pharmaceuticals Enter into Exclusive License Agreement for JR-141 in the United States, Europe, and Latin America
- JCR Pharmaceuticals Receives Orphan Drug Designation from the Ministry of Health, Labour and Welfare of Japan for Givinostat for Duchenne Muscular Dystrophy
- FY2026 First Quarter Results Briefing Session Material
- JCR Pharmaceuticals - Notice Regarding the Completion of Payment for the Disposition of Treasury Stock as Restricted Stock Compensation
- JCR Pharmaceuticals Receives Marketing Authorization in the United Arab Emirates for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome
Follow JCR Pharmaceuticals into a list and get an email when it puts out news.
Follow JCR Pharmaceuticals